RCKTHealthcare · BiotechnologyThe 14 Wall Street analysts covering Rocket Pharmaceuticals, Inc. hold a median 12-month price target of $9.5 — +274.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 28 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Rocket Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (83): Sales and profits are climbing, and climbing faster than before.
Momentum (37): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on RCKT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +274.0% from it.
Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Oct 2026 | Goldman Sachs | Upgrade | Neutral | $3.00 → $4.00 |
| 7 Oct 2026 | Chardan Capital | Maintains | Buy | $11 |
| 7 Oct 2026 | Leerink Partners | Maintains | Market Perform | $7.00 → $4.00 |
| 7 Oct 2026 | Wedbush | Reiterates | Outperform | $15 |
| 16 Sept 2026 | Needham | Upgrade | Buy | $9.00 |
| 16 Sept 2026 | Needham | Upgrade | Buy | — |
| 16 Sept 2026 | Wedbush | Reiterates | Outperform | — |
| 16 Sept 2026 | Wedbush | Reiterates | Outperform | $15 |
| 15 Sept 2026 | Chardan Capital | Maintains | Buy | — |
| 15 Sept 2026 | Chardan Capital | Maintains | Buy | $11 |
| 1 Sept 2026 | Chardan Capital | Maintains | Buy | $11 |
| 1 Sept 2026 | Chardan Capital | Maintains | Buy | — |
| 11 Aug 2026 | Wedbush | Maintains | Outperform | $16 → $15 |
| 11 Aug 2026 | Wedbush | Maintains | Outperform | — |
| 11 May 2026 | Chardan Capital | Maintains | Buy | — |
| 11 May 2026 | Chardan Capital | Maintains | Buy | $11 |
| 30 Mar 2026 | B of A Securities | Maintains | Buy | — |
| 27 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 2 Mar 2026 | Goldman Sachs | Maintains | Sell | — |
| 27 Feb 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RCKT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Rocket Pharmaceuticals, Inc. returned −32.8% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 84% of US stocks
Cheaper than 78% of US stocks
Cheaper than 63% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 40% of US stocks
Higher than 15% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Rocket Pharmaceuticals, Inc. has a market value of $268.9M and an enterprise value of $10.0M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$17.3M.
Diluted earnings per share, trailing twelve months: $−0.17.
Free cash flow in the twelve months to 30 June 2026: −$170.4M.
Trailing P/E: −1.2×; forward P/E: −1.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Rocket Pharmaceuticals, Inc. employs 202 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Rocket Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Rocket Pharmaceuticals announced it will participate in Chardan's 10th Annual Healthcare Conference on October 20, 2026, with a panel appearance at 11:30 a.m. ET and investor meetings.
Why it matters — The conference participation gives RCKT watchers a scheduled opportunity to hear from the company and engage with its representatives.
Rocket Pharmaceuticals shares rose 4% on Wednesday after the company secured access to up to $150 million through a credit facility with Hercules Capital. The facility is intended to support its pivotal Phase 2 RP-A501 study for Danon disease and its broader cardiovascular pipeline.
Why it matters — The facility provides additional capital for Rocket's clinical study and cardiovascular pipeline.
Rocket Pharmaceuticals highlighted findings and development milestones for RP-A501 from its October 6 Danon disease investor webinar, including a defined path to completing an FDA-aligned pivotal Phase 2 trial and sustained biological activity in longer-term Phase 1 follow-up.
Why it matters — The update provides RCKT watchers with information on RP-A501’s clinical findings and the planned pivotal-trial path.
Seeking Alpha published a transcript discussing Rocket Pharmaceuticals’ Danon disease program, with a focus on the RP-A501 pivotal trial and preliminary clinical data.
Why it matters — The transcript concerns the development and clinical data for a Rocket Pharmaceuticals program.
Rocket Pharmaceuticals outlined updated clinical, regulatory, and commercial plans for its investigational Danon disease gene therapy RP-A501. The update included longer-term Phase I findings, preliminary Phase II observations, and an FDA-aligned pivotal study design.
Why it matters — The update provides RCKT watchers with information on the therapy’s clinical progress and planned pivotal study.
The 14 Wall Street analysts covering Rocket Pharmaceuticals, Inc. have a median 12-month price target of $9.5, with estimates ranging from $2.95 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Rocket Pharmaceuticals, Inc., 7 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Rocket Pharmaceuticals, Inc. 53 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Rocket Pharmaceuticals, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (83 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +274.0% from the last close, and Ticker Nerd's factor model ranks Rocket Pharmaceuticals, Inc. 53 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Rocket Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RCKT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.95 to $15 over the next 12 months.
Rocket Pharmaceuticals, Inc. returned -32.8% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with an emphasis on inherited cardiovascular disorders, hematology, and immunology.
The most recent item we track (Business Wire, 15 Oct 2026): "Rocket Pharmaceuticals to Participate in Chardan's 10th Annual Healthcare Conference". Rocket Pharmaceuticals announced it will participate in Chardan's 10th Annual Healthcare Conference on October 20, 2026, with a panel appearance at 11:30 a.m. ET and investor meetings.
Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with an emphasis on inherited cardiovascular disorders, hematology, and immunology. The company’s programs are built around advanced viral vector platforms designed to address the underlying genetic cause of serious pediatric and inherited conditions. Rocket Pharmaceuticals currently develops and advances investigational and commercial genetic medicines, including therapies for disorders such as Danon disease, BAG3-related dilated cardiomyopathy, Fanconi anemia, and severe leukocyte adhesion deficiency-I. The company is also involved in manufacturing, clinical development, and the commercialization of its gene therapy products. Headquartered in Cranbury, New Jersey, Rocket Pharmaceuticals plays a specialized role in the rare-disease market by targeting conditions with significant unmet medical need through precision genetic medicine.
CEO Dr. Gaurav D. Shah M.D. · 202 employees · United States · https://www.rocketpharma.com
